Clinical Analysis: 67-Year-Old Male with Melena, Epigastric Pain, and Neurological Deficits
Provisional Working Impression (PWI)
This patient most likely has NSAID-induced peptic ulcer disease with acute upper gastrointestinal bleeding complicated by hemorrhagic stroke secondary to severe anemia and hypovolemic shock. The combination of melena, epigastric pain, pale conjunctiva, and etoricoxib (Arcoxia) use in an elderly hypertensive patient strongly suggests NSAID-related gastroduodenal ulceration with significant hemorrhage 1, 2. The quadriplegia and transient anomia indicate a catastrophic neurological event—most likely hemorrhagic stroke precipitated by severe anemia causing cerebral hypoperfusion, potentially with hemorrhagic conversion 2.
Three Differential Diagnoses with Comprehensive Explanations
1. NSAID-Induced Peptic Ulcer Disease with Complicated Upper GI Bleeding and Secondary Hemorrhagic Stroke (Most Likely)
Gastrointestinal Component:
Etoricoxib (Arcoxia) is a COX-2 selective NSAID that carries significant gastrointestinal toxicity risk, particularly in elderly patients 1. Although COX-2 inhibitors were developed to reduce GI adverse events compared to traditional NSAIDs, the protection against gastrointestinal bleeding is incomplete 1.
Melena is the most common presentation of upper GI bleeding and signifies bleeding proximal to the ligament of Treitz 3, 4. The epigastric dull, nonradiating pain strongly suggests a gastroduodenal source 2.
The patient's age (67 years), hypertension, and NSAID use place him at extremely high risk for NSAID-associated adverse events 1. A recent study implicated NSAIDs in 23.5% of hospitalizations for adverse drug reactions in older adults 1.
Progressive generalized weakness and lightheadedness reflect hemodynamic compromise from acute blood loss 2, 4. Pale palpebral conjunctiva confirms significant anemia 4.
The vital signs (BP 140/90 mmHg, absence of documented tachycardia in the presentation but hyperactive bowel sounds) suggest compensated shock or early decompensation 5, 4. The Rockall score identifies shock (pulse >100 bpm, systolic BP <100 mmHg) as an independent predictor of mortality 5.
Hyperactive bowel sounds are consistent with blood in the GI tract stimulating peristalsis 2.
Neurological Component:
Quadriplegia with transient anomia indicates bilateral hemispheric involvement, brainstem hemorrhage, or global hypoxic-ischemic injury 2. In the setting of severe GI bleeding, hemorrhagic stroke is more probable than ischemic stroke 2.
Severe anemia precipitates cerebral hypoperfusion, increasing the risk of hemorrhagic conversion 2. Hypovolemic shock from massive GI bleeding can trigger cerebral ischemia that subsequently hemorrhages 2.
Expressive aphasia (anomia) localizes to the dominant frontal lobe, typically the left hemisphere 2.
The patient's hypertension (on losartan and amlodipine) is a major risk factor for hemorrhagic stroke, and the acute anemia may have destabilized previously controlled blood pressure.
Drug Interactions and Toxicity:
Colchicine can cause gastrointestinal adverse effects including cramping, nausea, diarrhea, abdominal pain, and vomiting in up to 20% of patients 6. However, colchicine-induced myelosuppression typically presents with cytopenia rather than acute bleeding 7.
The combination of etoricoxib and colchicine in a patient with potential renal impairment (nocturia, polyuria, urinary urgency suggest possible CKD) increases the risk of drug accumulation and toxicity 6, 7.
2. Gastric Malignancy (Adenocarcinoma) with Acute Bleeding and Metastatic Disease
Rationale:
Gastric cancer commonly presents with acute bleeding (hematemesis or melena) and may arise directly from the tumor 8, 9. Patients with acute severe bleeding should undergo prompt endoscopic assessment 8, 9.
Epigastric pain, progressive weakness, constipation, and bloating are consistent with gastric malignancy 8. The slightly distended abdomen and hepatomegaly raise concern for metastatic disease, particularly hepatic metastases 8.
Chronic blood loss from gastric cancer causes iron-deficiency anemia, manifesting as pale conjunctiva and generalized weakness 9, 10.
The patient's age (67 years) places him in the higher-risk category for gastric cancer 5. Increasing age is closely related to mortality in upper GI bleeding, with deaths rare under age 40 but reaching 30% in patients over 90 5.
Hepatomegaly could represent metastatic spread, though it could also be related to chronic liver disease or other causes 8.
Neurological Component:
- Paraneoplastic syndromes or metastatic disease to the brain could explain the neurological findings, though quadriplegia is less typical. Alternatively, severe anemia from chronic tumor bleeding could precipitate stroke 2.
Limitations:
The absence of weight loss, nausea, vomiting, or coffee-ground emesis makes malignancy less likely as the primary diagnosis 8, 4. However, early gastric cancer may present with minimal symptoms.
Endoscopic evaluation with biopsy is essential for diagnosis 8. Universal testing for MSI/MMR and HER2 is recommended in all newly diagnosed gastric adenocarcinoma patients 8.
3. Colchicine Toxicity with Myelosuppression and Secondary Complications
Rationale:
Colchicine can cause serious toxic manifestations including myelosuppression, gastrointestinal toxicity, and injury to renal, hepatic, and central nervous systems 6, 7. These most often occur with excessive accumulation or overdosage 6.
The patient is on multiple medications (losartan, amlodipine) and has comorbidities (hypertension, gouty arthritis) that may affect colchicine metabolism 6, 7. Colchicine is a substrate of P-glycoprotein (P-gp) and is metabolized by CYP3A4 6.
Renal impairment (suggested by nocturia, polyuria, urinary urgency) significantly increases the risk of colchicine accumulation and toxicity 7. Out of 47 patients with colchicine-induced myelosuppression, 21 (44.7%) had renal impairment 7.
Gastrointestinal adverse effects are the most frequent side effects of colchicine, presenting within 24 hours in up to 20% of patients 6. Symptoms include cramping, nausea, diarrhea, abdominal pain, and vomiting 6.
Colchicine-induced myelosuppression can present with anemia, leukopenia, thrombocytopenia, and pancytopenia 6, 7, 11. The sequential involvement of blood cell lines (thrombocytopenia, then leukopenia, then anemia) suggests direct toxicity from drug accumulation 11.
Neurological manifestations of colchicine toxicity include sensory-motor neuropathy 6, though quadriplegia is not a typical presentation.
Drug Interactions:
Etoricoxib may interact with colchicine, though this is not well-documented 12. Etoricoxib has been reported to cause immune hemolytic anemia and acute kidney failure 12.
The combination of colchicine with febuxostat (not used in this patient) has been studied and does not appear to increase hepatotoxicity 13. However, allopurinol and colchicine together have been associated with fulminant liver failure, particularly in patients with CKD 14.
Limitations:
Melena and acute GI bleeding are not typical presentations of colchicine toxicity, which more commonly causes diarrhea and abdominal cramping 6, 7.
The temporal relationship between colchicine initiation and symptom onset is unclear from the history provided. Colchicine-induced myelosuppression typically develops over weeks to months 7, 11.
Quadriplegia is not a recognized manifestation of colchicine toxicity, making this diagnosis less likely as the primary etiology 6.
Critical Management Priorities
Immediate Resuscitation and Stabilization:
Initiate aggressive volume resuscitation with crystalloids and blood transfusion 15, 4. Blood transfusions should be administered when hemoglobin is ≤70 g/L, with a target of 70–90 g/L 15.
In elderly patients with cardiovascular comorbidities (hypertension), a higher transfusion threshold (80–100 g/L) may be warranted 15.
Monitor vital signs continuously for signs of shock (tachycardia >100 bpm, systolic BP <100 mmHg) 5, 4.
Urgent Diagnostic Evaluation:
Perform urgent upper endoscopy (esophagogastroduodenoscopy) within 24 hours to identify the bleeding source and provide therapeutic intervention 8, 5, 9, 2. Endoscopy identifies a bleeding source in approximately 80% of cases 2.
Do NOT delay endoscopy for neurological workup; prompt GI intervention may mitigate the precipitating factor for stroke 2.
Obtain emergent non-contrast head CT to differentiate hemorrhagic from ischemic stroke 2. If CT is nondiagnostic, proceed to brain MRI 2.
Laboratory evaluation should include CBC, comprehensive metabolic panel (including renal and hepatic function), coagulation studies (PT/INR, aPTT), and blood type and crossmatch 8, 15.
Elevated BUN with normal or mildly elevated creatinine is characteristic of upper GI bleeding due to digestion of blood proteins 4.
Medication Management:
Immediately discontinue etoricoxib (Arcoxia) 1. NSAIDs are contraindicated in patients with active GI bleeding.
Review colchicine dosing and consider dose reduction or temporary discontinuation, particularly if renal impairment is confirmed 6, 7. Monitor for signs of colchicine toxicity (myelosuppression, elevated liver enzymes) 6, 7.
Initiate high-dose proton pump inhibitor (PPI) therapy 1, 9. Although PPIs reduce the risk of bleeding from gastric lesions, definitive data supporting their use in acute bleeding are limited 9.
Endoscopic Therapy:
Endoscopic treatment options include injection therapy, mechanical therapy (endoscopic clips), ablative therapy (argon plasma coagulation), or combination methods 8, 9. However, the rate of recurrent bleeding is very high in gastric cancer patients 8, 9.
If endoscopy is unsuccessful or contraindicated, consider angiographic embolization or external beam radiation therapy 8, 9.
Neurological Management:
Immediate neuro-imaging must precede any decision to anticoagulate, as assuming an ischemic stroke in the setting of severe anemia and GI bleeding could be catastrophic.
Consult neurology and neurosurgery urgently for management of hemorrhagic stroke and quadriplegia.
Common Pitfalls to Avoid
Do not attribute constipation to the primary pathology; it is more often secondary to dehydration, reduced oral intake, or iron supplementation 2.
Do not delay endoscopic evaluation while awaiting neurological studies, which can worsen bleeding outcomes 2.
Do not assume hematochezia always originates from a lower GI source; massive upper GI bleeding can also produce hematochezia 4.
Do not overlook drug interactions and toxicity in elderly patients on multiple medications 1, 6, 7. Colchicine and NSAIDs both carry significant risks in patients with renal impairment.
Do not miss the diagnosis of gastric malignancy; endoscopic biopsy is essential if a mass or ulcer is visualized 8.